
Pharmaceutical Agents in Surface and Drinking Water



Briefing for MWCOG Tee L. Guidotti Janet Phoenix Center for Risk Science and Public Health GWU SPHHS

Background

- We've known this was coming for years.
- Ecosystem effects and human health issue

Incomplete health data

- Typical of an emerging issue
- Health outcome data will be hard to obtain
- Systemic approach needed:
 - Risk assessment to address uncertainty
 - Risk management to control effluent
 - Risk communication and risk perception
- Pervasive distrust of water safety in DC
 - Substantially aggravated by lead issue
 - Falls within purview of Washington Aqueduct



Health Risk Potential

- Pharmaceuticals are designed to have a biological impact, but at relatively high concentrations
- Lack tests for many effects
 - EPA has tried for endocrine disruptors – controversy
 - Meaning of some in dispute
- Pharmaceutical residues may be transformed
 - Biotransformation in surface water
 - Reactions with free chlorine
- Chemical mixtures may have unpredictable effects.
 - Theoretical concern



This is not exactly a surprise.



Health Risk - Plausible

- Ecotoxicity more likely than human toxicity
- Most likely effects are endocrine disruption
 - Hormones and cell signaling
 - Can have effects at much lower levels than other chemicals: dosage issues and relevance of indicators
- Pharmaceuticals are present in very low concentrations: ppb, ppt
 1 ppb = 1 dro
 - Too low for most toxic effects
 - Allergic reactions if levels rise?
- Antibiotic-resistance?
 - Most likely where local accumulation
 - Documented for antibiotics in feed

1 ppb = 1 drop of water in an Olympic-sized swimming pool





Perception of Risk

- Perception, rather than data, and the section data, and the section data drives public reactions.
- Addressing perceptions
 - We have known about this problem for years.
 - Much is due to much improved measurement technology and surveys.
 - Health effects not so easy to rule out
- Need a comprehensive message on water quality.
 - Enormously complicated by the lead issue.
 - Strategic risk communication effort

Is it a threat to me and my family?

Management of Risk - National

- Coordinated approach to human health effects and contaminant mixtures (FDA, EPA, CDC, USGS)
- Integration of pharmaceuticals into the CDC's Environmental Health Tracking Program
- Interagency collaboration at the local, state and national level in conducting assessments
- Control agricultural practices that release antibiotics and steroids into source water.
- Change TSCA and integrate screening with FDA
 - Require pharmaceutical companies to assess the environmental impact of new pharmaceuticals.
 - Model should be REACH. This won't happen.

Management of Risk - Local

Pharmaceutical Take Back Programs

- Collaboration with pharmacists
- Proper disposal of medications
- Public education



- Removing barriers to take back programs.
- Invest in drinking and wastewater treatment upgrades and infrastructure.
- This is really a national issue, not a local one.
- Watershed protection and upstream management.

